SIRS-Lab

NEW YORK (GenomeWeb News) – Analytik Jena said today it has acquired all the assets of SIRS-Lab, a developer of molecular diagnostics for infectious diseases, which declared ins

NEW YORK (GenomeWeb News) – SIRS-Lab, a German molecular diagnostic developer, said today that it has begun insolvency proceedings and it is seeking an investor to commercialize its leading product, a test for the causative agent of sepsis.

Becton Dickinson said this week that its BD MAX MRSA molecular test has received a CLIA moderate complexity rating.

German molecular diagnostics firm SIRS-Lab this week commenced a 1,000-patient clinical study in its home country to evaluate Vyoo, the company's PCR- and microarray-based molecular test for causative agents of sepsis. Results from the study will support an application for regulatory approval in Europe.

The initial focus of the partnership will be on using molecular diagnostics to test for severe fungal blood stream infections and to evaluate the clinical impact and pharmacoeconomics of such an approach.

Roche gets FDA nod for dual-PCR HIV viral load test; Cepheid wins approval for S. aureus test; Viracor-IBT Labs launches Aspergillus PCR panel; SIRS-Lab, Analytik Jena partner on sepsis diagnostics

Analytik Jena's subsidiary will provide SIRS-Lab an instrument and associated reagents for a sepsis test currently undergoing a clinical study.

Sometimes genetic tests give inconclusive results and provide little reassurance to patients, the Associated Press reports.

Vox wonders whether gene-editing crops will be viewed similarly as genetically modified organisms of if people will give them a try.

In Science this week: research regulation and reporting requirement reform, and more.

NPR reports that government and private insurers are being slow to cover recently approved CAR-T cell therapies.